CONTINUED EFFICACY AND SAFETY THROUGH 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102): PRELIMINARY ANALYSIS

被引：0
|
作者：
Marcellin, Patrick [2 ]
Buti, Maria [3 ]
Krastev, Zahary [4 ]
Gurel, Selim [5 ]
Di Bisceglie, Adrian M. [6 ]
Odin, Joseph A. [7 ]
Dusheiko, Geoffrey M. [8 ]
Heathcote, E. Jenny [9 ]
Borroto-Esoda, Katyna [1 ]
Coombs, Derek H. [1 ]
Mondou, Elsa [1 ]
Anderson, Jane [1 ]
机构：
[1] Gilead Sci, Durham, NC USA
[2] Univ Paris, Hop Beaujon, Clichy, France
[3] Univ Vall Hebron & Ciberehd, Serv Med Interna Hepatol, Gen Hosp, Barcelona, Spain
[4] Univ Hosp St Ivan Rilsky, Sofia, Bulgaria
[5] Uludag Univ, Bursa, Turkey
[6] St Louis Univ, Sch Med, St Louis, MO USA
[7] Mt Sinai Sch Med, New York, NY USA
[8] Royal Free Hosp, London NW3 2QG, England
[9] Univ Toronto, Toronto, ON, Canada
来源：
HEPATOLOGY | 2010年 / 52卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
476
引用
收藏
页码：555A / 556A
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive patients with chronic hepatitis B
    Lim, Jihye
    Choi, Won-Mook
    Shim, Ju Hyun
    Lee, Danbi
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Choi, Jonggi
    JOURNAL OF HEPATOLOGY, 2022, 77 : S842 - S842
  • [32] HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment
    George, J.
    Gane, E. J.
    Sievert, W. S.
    Desmond, P. A.
    Crawford, D.
    Roberts, S. K.
    Strasser, S. I.
    Heathcote, E. J.
    Marcellin, P.
    Sorbel, J.
    Rousseau, F.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A126 - A126
  • [33] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide in patients with chronic hepatitis B and risk factors for TDF use
    Gane, E.
    Seto, W. K.
    Janssen, H.
    Caruntu, F. A.
    Kim, H. J.
    Abdurakhmanov, D.
    Nishiguchi, S.
    Andrzej, H.
    Bae, H.
    Mo, S.
    Suri, V.
    Gaggar, A.
    Flaherty, J. F.
    Kao, J-H
    Brunetto, M.
    Buti Ferret, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 42 - 43
  • [34] Safety of Tenofovir Disoproxil Fumarate (TDF) treatment for the entire pregnancy in mothers with active chronic hepatitis B or cirrhosis
    Pan, Calvin
    Liu, Min
    Cai, Haodong
    Yi, Wei
    HEPATOLOGY, 2013, 58 : 624A - 624A
  • [35] HBSAG KINETICS OF DECAY AND BASELINE CHARACTERISTICS OF HBEAG-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B FOLLOWING 3 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT
    Gane, E.
    Heathcote, E. J.
    Marcellin, P.
    Dusheiko, G.
    Jacobson, I.
    de Man, R.
    Zeuzem, S.
    Nikolaidis, P.
    Sorbel, J.
    Mondou, E.
    Anderson, J.
    Rousseau, F.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S388 - S388
  • [36] A PHASE 3 STUDY COMPARING SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) WITH CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB): WEEK 48 EFFICACY AND SAFETY RESULTS
    Chan, Henry Lik Yuen
    Lampertico, Pietro
    Buti, Maria
    Fung, Scott
    Ahn, Sang Hoon
    Chuang, Wan-Long
    Tak, Won Young
    Ramji, Alnoor
    Chen, Chi-Yi
    Tam, Edward
    Bae, Ho
    Ma, Xiaoli
    Flaherty, John
    Gaggar, Anuj
    Lau, Audrey
    Feierbach, Becket
    Wu, George
    Suri, Vithika
    Subramanian, Mani
    Huy Trinh
    Yoon, Seung-Kew
    Agarwal, Kosh
    Lim, Young-Suk
    GUT, 2019, 68 : A142 - A143
  • [37] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-POSITIVE PATIENTS: A GLOBAL PHASE 3 STUDY
    Agarwal, Kosh
    Fung, Scott
    Seto, Wai-Kay
    Lim, Young-Suk
    Gane, Edward
    Janssen, Harry L.
    Chuang, Wan-Long
    Bae, Ho
    Yoon, Ki Tae
    Flaherty, John F.
    Lau, Audrey
    Gaggar, Anuj
    Suri, Vithika
    Cathcart, Andrea
    Lin, Lanjia
    Chan, Alain
    Shalimar, Mani Subramanian
    Furusyo, Norihiro
    Buti, Maria
    Chan, Henry L.
    GASTROENTEROLOGY, 2017, 152 (05) : S1085 - S1086
  • [38] Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis
    Wang, Chia
    Buti, Maria
    Hadziyannis, Stephanos J.
    Mathurin, Philipe
    Sherman, Morris
    Strasser, Simone I.
    Petersen, Joerg
    Tong, Myron J.
    Sorbel, Jeff
    Mondou, Elsa
    Anderson, Jane
    Rousseau, Franck
    GASTROENTEROLOGY, 2008, 134 (04) : A808 - A809
  • [39] Tenofovir disoproxil fumarate (TDF) for the treatment of HBcAg-negative chronic hepatitis B: Week 72 TDF data and week 24 adefovir dipivoxil switch data (Study 102)
    Marcellin, Patrick
    Jacobson, Ira M.
    Tsai, Naoky
    Bzowej, Natalie
    Habersetzer, Francois
    Senturk, Hakan
    Moyes, Christopher D.
    Teuber, Gerlinde
    Sorbel, Jeff
    Anderson, Jane
    Mondou, Elsa
    Quinn, Joe
    Rousseau, Franck
    GASTROENTEROLOGY, 2008, 134 (04) : A808 - A808
  • [40] Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis
    Butil, M.
    Hadziyannis, S.
    Mathurin, P.
    Urbanek, P.
    Sherman, M.
    Strasser, S.
    Wang, C.
    Petersen, J.
    Sorbel, J.
    Mondou, E.
    Anderson, J.
    Rousseau, F.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S33 - S33
12345